Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07815054

Enrollment

200

Registered

2026-09-11

Start date

2026-10-01

Completion date

2029-09-30

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma (HCC)

Keywords

Hepatocellular Carcinoma, microwave ablation, Progression-Free Survival, Overall Survival, Diaphragm Hydrodissection

Brief summary

The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical resection for hepatocellular carcinoma. The main questions it aims to answer are: Is hydrodissection-assisted microwave ablation safe and effective for treating hepatocellular carcinoma? How does the therapeutic effect of hydrodissection-assisted microwave ablation compare with surgical resection for hepatocellular carcinoma? Patients who receive either microwave ablation or surgical resection will Undergo a 2-year follow-up period.

Interventions

PROCEDUREMicrowave Ablation Assisted by Diaphragm Hydrodissection

For subphrenic hepatocellular carcinoma treated with microwave ablation, ultrasound-guided injection of normal saline into the diaphragm is performed during ablation to establish a hydrodissection barrier and optimise lesion visualisation.

PROCEDURESurgical Resection

Patients with subphrenic hepatocellular carcinoma who undergo surgical resection are managed according to clinical diagnostic and therapeutic standards for hepatocellular carcinoma.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Child-Pugh grade A or B liver function.Single hepatic lesion with a maximum diameter ≤ 5 cm.The lesion is located in the subphrenic region with a distance ≤ 10 mm from the right diaphragm.

Exclusion criteria

Presence of extrahepatic metastasis or other concomitant malignant tumors.Presence of severe cardiac, pulmonary, or renal dysfunction.Platelet count \< 50×10⁹/L with irreversible coagulation disorders. Patients with incomplete imaging or clinical medical data.

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival (PFS)	Up to 2 years after treatment	the time from initiation of treatment to disease progression or death.

Secondary

Measure	Time frame	Description
Overall survival (OS)	Up to 2 years after treatment	the time from initiation of treatment to death, loss to follow-up, or last follow-up.

Contacts

CONTACTdezhi Zhang Associate Chief Physician, MD

dezhi@jlu.edu.cn+8618186876068

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026